JP2017533249A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533249A5
JP2017533249A5 JP2017525078A JP2017525078A JP2017533249A5 JP 2017533249 A5 JP2017533249 A5 JP 2017533249A5 JP 2017525078 A JP2017525078 A JP 2017525078A JP 2017525078 A JP2017525078 A JP 2017525078A JP 2017533249 A5 JP2017533249 A5 JP 2017533249A5
Authority
JP
Japan
Prior art keywords
methyl
oxo
alkyl
phenyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017525078A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533249A (ja
JP6669745B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/060007 external-priority patent/WO2016077380A1/en
Publication of JP2017533249A publication Critical patent/JP2017533249A/ja
Publication of JP2017533249A5 publication Critical patent/JP2017533249A5/ja
Application granted granted Critical
Publication of JP6669745B2 publication Critical patent/JP6669745B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017525078A 2014-11-10 2015-11-10 ブロモドメインのインヒビターとしての置換ピロロピリジン Expired - Fee Related JP6669745B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462077707P 2014-11-10 2014-11-10
US62/077,707 2014-11-10
PCT/US2015/060007 WO2016077380A1 (en) 2014-11-10 2015-11-10 Substituted pyrrolopyridines as inhibitors of bromodomain

Publications (3)

Publication Number Publication Date
JP2017533249A JP2017533249A (ja) 2017-11-09
JP2017533249A5 true JP2017533249A5 (enExample) 2018-12-20
JP6669745B2 JP6669745B2 (ja) 2020-03-18

Family

ID=54602075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525078A Expired - Fee Related JP6669745B2 (ja) 2014-11-10 2015-11-10 ブロモドメインのインヒビターとしての置換ピロロピリジン

Country Status (6)

Country Link
US (1) US10150767B2 (enExample)
EP (1) EP3218374B1 (enExample)
JP (1) JP6669745B2 (enExample)
CN (1) CN107108614B (enExample)
MA (1) MA40940A (enExample)
WO (1) WO2016077380A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40943A (fr) * 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3218376B1 (en) 2014-11-10 2019-12-25 Genentech, Inc. Bromodomain inhibitors and uses thereof
JP6709792B2 (ja) 2015-01-29 2020-06-17 ジェネンテック, インコーポレイテッド 治療用化合物およびその使用
US11319318B2 (en) 2015-03-05 2022-05-03 Boehringer Ingelheim International Gmbh Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
ES2793239T3 (es) 2016-04-15 2020-11-13 Abbvie Inc Inhibidores del bromodominio
EP3892272B1 (en) 2016-04-22 2024-07-24 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for degradation of egfr and methods of use
CN110167939B (zh) * 2017-01-11 2021-12-31 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
EP3609896A4 (en) * 2017-04-14 2020-11-04 AbbVie Inc. BROMODOMAIN INHIBITORS
CN108976278B (zh) * 2017-06-05 2021-04-06 海创药业股份有限公司 一种嵌合分子及其制备和应用
KR20200101434A (ko) * 2017-12-20 2020-08-27 베타 파머수티컬 컴퍼니 리미티드 브로모도메인 단백질 억제제로서 작동하는 화합물 및 조성물
WO2019154329A1 (zh) * 2018-02-06 2019-08-15 上海海和药物研究开发有限公司 具有bet抑制活性的化合物及其制备方法和用途
CN108465108B (zh) * 2018-03-12 2020-07-07 上海宇玫博生物科技有限公司 一种预防或治疗脑胶质瘤的特异性基因靶点
US10442799B1 (en) 2018-04-07 2019-10-15 Fuqiang Ruan Heterocyclic compounds and uses thereof
WO2020007322A1 (zh) * 2018-07-04 2020-01-09 清华大学 一种靶向降解bet蛋白的化合物及其应用
CN110776508B (zh) * 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
CN110818609A (zh) * 2018-08-11 2020-02-21 中国药科大学 3-乙酰基吲哚类brpf1抑制剂的制备方法及其用途
US20210198629A1 (en) * 2018-08-20 2021-07-01 University Of Georgia Research Foundation, Inc. Compositions and methods for increasing beiging of white adipose tissue
CN109125729A (zh) * 2018-09-06 2019-01-04 苏州吉玛基因股份有限公司 与非小细胞肺癌诊疗相关的基因BRD9及其siRNAs和应用
WO2020132004A1 (en) * 2018-12-20 2020-06-25 Saint Louis University Bet inhibitors for modulating dux4 expression in fshd
EP3958867B1 (en) * 2019-04-24 2024-06-26 Convergene Llc Small molecule bromodomain inhibitors and uses thereof
GB201905721D0 (en) * 2019-04-24 2019-06-05 Univ Dundee Compounds
US11171132B2 (en) * 2019-10-03 2021-11-09 Globalfoundries U.S. Inc. Bi-directional breakdown silicon controlled rectifiers
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
WO2022012456A1 (en) * 2020-07-17 2022-01-20 Chengdu Easton Biopharmaceuticals Co., Ltd. Novel heterocyclic compounds as bet inhibitors
TW202237095A (zh) 2020-12-03 2022-10-01 德商艾斯巴赫生物有限公司 Alc1抑制劑及與parpi之協同性
CN115232123A (zh) * 2021-04-23 2022-10-25 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
WO2023275542A1 (en) * 2021-06-29 2023-01-05 Tay Therapeutics Limited Pyrrolopyridone derivatives useful in the treatment of cancer
CN115611890B (zh) * 2021-07-15 2024-05-31 成都硕德药业有限公司 一种新型噻吩类bet溴结构域抑制剂、其制备方法及医药用途
TW202330519A (zh) * 2021-09-29 2023-08-01 香港商德琪研發有限公司 作為tam抑制劑的吡唑并吡啶化合物
CN119365198A (zh) 2022-05-02 2025-01-24 艾斯巴赫生物有限公司 ALC1抑制剂的用途和与PARPi的协同作用
CN117304205B (zh) * 2022-06-20 2026-05-05 中国科学院广州生物医药与健康研究院 一种苯并咪唑类三元并环化合物、其药学上可接受的盐及其应用
CN117304204B (zh) * 2022-06-20 2026-02-10 中国科学院广州生物医药与健康研究院 一种苯并咪唑类三元并环化合物、其药学上可接受的盐及其应用
IL321504A (en) * 2022-12-23 2025-08-01 Tay Therapeutics Ltd Selective beta inhibitors and their uses
WO2024193527A1 (zh) * 2023-03-20 2024-09-26 山东新时代药业有限公司 作为溴结构域抑制剂的吡咯并[2,3-c]吡啶类化合物

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
GB9300059D0 (en) 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
DK0659439T3 (da) 1993-12-24 2002-01-14 Merck Patent Gmbh Immunkonjugater
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
HU216142B (hu) 1994-07-21 1999-04-28 Akzo Nobel N.V. Ciklusos keton-peroxidokat tartalmazó kompozíciók, és azok alkalmazása (ko)polimerek módosítására
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
EP0836605B1 (en) 1995-07-06 2002-02-06 Novartis AG Pyrrolopyrimidines and processes for the preparation thereof
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
JP3370340B2 (ja) 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
DE69716916T2 (de) 1996-07-13 2003-07-03 Glaxo Group Ltd., Greenford Kondensierte heterozyklische verbindungen als protein kinase inhibitoren
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2201484T3 (es) 1997-05-06 2004-03-16 Wyeth Holdings Corporation Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal.
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
NZ503991A (en) 1997-11-06 2001-11-30 American Cyanamid Co Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps
ES2188254T3 (es) 1998-11-19 2003-06-16 Warner Lambert Co N-(4-(3-chloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quin azolin-6-il)-acrilamada, un inhibidor irreversible de tirosina quinasas.
EP1953147A1 (en) 2005-11-21 2008-08-06 Japan Tobacco, Inc. Heterocyclic compound and medicinal application thereof
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20140094456A1 (en) * 2012-10-02 2014-04-03 Intermune, Inc. Anti-fibrotic pyridinones
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014125408A2 (en) * 2013-02-12 2014-08-21 Aurigene Discovery Technologies Limited Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
EP2970285B1 (en) 2013-03-11 2019-04-17 AbbVie Inc. Fused tetracyclic bromodomain inhibitors
CN105026403B (zh) * 2013-03-12 2018-05-18 艾伯维公司 四环布罗莫结构域抑制剂
CN104211639A (zh) 2013-06-05 2014-12-17 中国科学院上海药物研究所 一类炔基杂环类化合物及其应用
JP6386035B2 (ja) 2013-06-12 2018-09-05 ヴィアメット ファーマスーティカルズ(エヌシー),インコーポレイテッド 金属酵素阻害剤化合物
PE20160540A1 (es) * 2013-06-28 2016-06-11 Abbvie Inc Inhibidores de bromodominios
WO2015081280A1 (en) * 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
US9399640B2 (en) * 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
US20150148372A1 (en) * 2013-11-26 2015-05-28 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
MY180775A (en) * 2014-04-23 2020-12-09 Incyte Corp 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
MA40943A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3218376B1 (en) 2014-11-10 2019-12-25 Genentech, Inc. Bromodomain inhibitors and uses thereof
WO2016086200A1 (en) * 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
HK1245677A1 (zh) 2015-01-23 2018-08-31 Aclaris Therapeutics, Inc. 用於治疗炎症和癌症的杂环itk抑制剂
JP6709792B2 (ja) 2015-01-29 2020-06-17 ジェネンテック, インコーポレイテッド 治療用化合物およびその使用

Similar Documents

Publication Publication Date Title
JP2017533248A5 (enExample)
JP2017533250A5 (enExample)
JP2019516757A5 (enExample)
JP2019516759A5 (enExample)
JP2017530176A5 (enExample)
JP6669745B2 (ja) ブロモドメインのインヒビターとしての置換ピロロピリジン
JP2017526696A5 (enExample)
JP2018501287A5 (enExample)
JP2017537100A5 (enExample)
TWI699355B (zh) 喹唑啉化合物
KR101258426B1 (ko) 세포 증식과 관련된 질환 치료용 배합물
JP6669744B2 (ja) ブロモドメインのインヒビターとしての置換ピロロピリジン
TWI373465B (en) Methods of administering pirfenidone therapy
AU2008236562B2 (en) Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K alpha
JP6639497B2 (ja) ブロモドメインインヒビターおよびその使用
TWI556820B (zh) Hsp90抑制劑之組合
AU2018226470A1 (en) Compounds for treatment of cancer
JP6360881B2 (ja) 触媒的mtorc1/2阻害薬及びオーロラaキナーゼの選択的阻害薬の組合せ
JP2019516757A (ja) Cbp/ep300の複素環式インヒビターおよびがんの処置におけるそれらの使用
JP2019512535A5 (enExample)
JP2009515852A5 (enExample)
JP2015500209A5 (enExample)
TW201000103A (en) Combinations comprising methotrexate and DHODH inhibitors
JP2017501983A5 (enExample)
CA3023392C (en) Combination of ppar agonist and p38 kinase inhibitor for treating cancer